News
![Form 8.3 - The Vanguard Group, Inc.: Vistry Group plc](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Form 8.3 - The Vanguard Group, Inc.: Vistry Group plc
Form 8.3 - The Vanguard Group, Inc.: Vistry Group plc
![Form 8.3 - The Vanguard Group, Inc.: Micro Focus International plc](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
Form 8.3 - The Vanguard Group, Inc.: Micro Focus International plc
Form 8.3 - The Vanguard Group, Inc.: Micro Focus International plc
![Form 8.3 - The Vanguard Group, Inc.: Tullow Oil plc](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Form 8.3 - The Vanguard Group, Inc.: Tullow Oil plc
Form 8.3 - The Vanguard Group, Inc.: Tullow Oil plc
![Silence Therapeutics to Participate in September Investment Conferences: https://mms.businesswire.com/media/20220126005163/en/1338762/5/Silence-Logo-FINAL-rgb.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK1BjVnc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--be75b7d9b4c0e9435a1d58c043c3c8d9b8f5a45e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Silence-Logo-FINAL-rgb.jpg?locale=us)
Silence Therapeutics to Participate in September Investment Conferences
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the
![Form 8.3 - The Vanguard Group, Inc.: Shaftesbury plc](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Form 8.3 - The Vanguard Group, Inc.: Shaftesbury plc
Form 8.3 - The Vanguard Group, Inc.: Shaftesbury plc
![DGAP-News: Cryptology’s estimated NAV per share as of 07/09/2022 is €5.03](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
DGAP-News: Cryptology’s estimated NAV per share as of 07/09/2022 is €5.03
DGAP-News: Cryptology’s estimated NAV per share as of 07/09/2022 is €5.03
![Form 8.3 - The Vanguard Group, Inc.: Meggitt plc](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Form 8.3 - The Vanguard Group, Inc.: Meggitt plc
Form 8.3 - The Vanguard Group, Inc.: Meggitt plc
![Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
![Form 8.3 - The Vanguard Group, Inc.: HomeServe plc](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Form 8.3 - The Vanguard Group, Inc.: HomeServe plc
Form 8.3 - The Vanguard Group, Inc.: HomeServe plc
![Form 8.3 - The Vanguard Group, Inc.: ContourGlobal plc](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Form 8.3 - The Vanguard Group, Inc.: ContourGlobal plc
Form 8.3 - The Vanguard Group, Inc.: ContourGlobal plc
![Form 8.3 - The Vanguard Group, Inc.: Euromoney Institutional Investor plc](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Form 8.3 - The Vanguard Group, Inc.: Euromoney Institutional Investor plc
Form 8.3 - The Vanguard Group, Inc.: Euromoney Institutional Investor plc
![Form 8.3 - The Vanguard Group, Inc.: Darktrace plc](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Form 8.3 - The Vanguard Group, Inc.: Darktrace plc
Form 8.3 - The Vanguard Group, Inc.: Darktrace plc
![Silence Therapeutics Announces FDA Fast Track Designation for SLN124, a Novel Investigational siRNA Therapy for the Treatment of Polycythemia Vera: https://mms.businesswire.com/media/20220126005163/en/1338762/5/Silence-Logo-FINAL-rgb.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBK1BjVnc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--be75b7d9b4c0e9435a1d58c043c3c8d9b8f5a45e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Silence-Logo-FINAL-rgb.jpg?locale=us)
Silence Therapeutics Announces FDA Fast Track Designation for SLN124, a Novel Investigational siRNA Therapy for the Treatment of Polycythemia Vera
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the
![Form 8.3 - The Vanguard Group, Inc.: Countryside Partnerships plc](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Form 8.3 - The Vanguard Group, Inc.: Countryside Partnerships plc
Form 8.3 - The Vanguard Group, Inc.: Countryside Partnerships plc
![Form 8.3 - The Vanguard Group, Inc.: Capricorn Energy plc](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Form 8.3 - The Vanguard Group, Inc.: Capricorn Energy plc
Form 8.3 - The Vanguard Group, Inc.: Capricorn Energy plc
![Form 8.3 - The Vanguard Group, Inc.: Capital & Counties Properties plc](/assets/news/news14-e52b56a6adda780de8ab40d75cabe14dcfa77fc9676e986401297a29e68c991e.png)
Form 8.3 - The Vanguard Group, Inc.: Capital & Counties Properties plc
Form 8.3 - The Vanguard Group, Inc.: Capital & Counties Properties plc
![Form 8.3 - The Vanguard Group, Inc.: Brewin Dolphin Holdings plc](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Form 8.3 - The Vanguard Group, Inc.: Brewin Dolphin Holdings plc
Form 8.3 - The Vanguard Group, Inc.: Brewin Dolphin Holdings plc
![Form 8.3 - The Vanguard Group, Inc.: Biffa plc](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
Form 8.3 - The Vanguard Group, Inc.: Biffa plc
Form 8.3 - The Vanguard Group, Inc.: Biffa plc
![Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
Form 8.3 - The Vanguard Group, Inc.: AVEVA Group plc
![Form 8.3 - The Vanguard Group, Inc.: Avast plc](/assets/news/news17-d49b9ce9c87babddea210274f0f8d00a1cf706146ef6382020cc7ece83b76f6c.png)
Form 8.3 - The Vanguard Group, Inc.: Avast plc
Form 8.3 - The Vanguard Group, Inc.: Avast plc
![Chelverton UK Dividend Trust plc: DIV-Dividend Declaration](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Chelverton UK Dividend Trust plc: DIV-Dividend Declaration
Chelverton UK Dividend Trust plc: DIV-Dividend Declaration
![Chelverton UK Dividend Trust plc: Net Asset Value(s)](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Chelverton UK Dividend Trust plc: Net Asset Value(s)
Chelverton UK Dividend Trust plc: Net Asset Value(s)
![Chelverton UK Dividend Trust plc: RAG-Result of AGM](/assets/news/news5-af8c677c86bb4b693f58afef33877e6f798ff0d7e2b4fa69b6e89960549b5ee6.png)
Chelverton UK Dividend Trust plc: RAG-Result of AGM
Chelverton UK Dividend Trust plc: RAG-Result of AGM
![Form 8 (OPD) - Schneider Electric SE](/assets/news/news4-fce0efe65d8ba787508ef718c0a20bed51e468dbc656c188c43e13f15b4a4f53.png)
Form 8 (OPD) - Schneider Electric SE
Form 8 (OPD) - Schneider Electric SE
![Rights and Issues Investment Trust PLC: Net Asset Value(s)](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Rights and Issues Investment Trust PLC: Net Asset Value(s)
Rights and Issues Investment Trust PLC: Net Asset Value(s)